#148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the ITP

ℹ️ EPISODE INFO

Released

February 8, 2021

Duration

2h 14m

Channel

Peter Attia MD

Watch on YouTube

▶ Open ↗

📝 EPISODE DESCRIPTION

Richard Miller is a professor of pathology and the Director of the Center for Aging Research at the University of Michigan. He is one of the architects of the NIA-funded Interventions Testing Programs (ITPs) animal study test protocol. In this episode, Rich goes through the results of the long list of molecules tested by the ITP—including rapamycin, metformin, nicotinamide riboside, an SGLT-2 inhibitor called canagliflozin, and more. Many of the discussed outcomes have had surprising outcomes—both positive and negative findings. We discuss: 00:00:00 - Intro 00:03:45 - Rich’s interest in aging, and how Hayflick’s hypothesis skewed aging research 00:15:00 - Dispelling the myth that aging can’t be slowed 00:29:00 - The Interventions Testing Program—A scientific framework for testing whether drugs extend lifespan in mice 00:38:45 - Testing aspirin in the first ITP cohort 00:44:45 - Rapamycin: results from ITP studies, dosing considerations, and what it tells us about early- vs. late-life interventions 01:07:15 - Acarbose as a potential longevity agent by virtue of its ability to block peak glucose levels 01:15:45 - Resveratrol: why it received so much attention as a longevity agent, and the takeaways from the negative results of the ITP study 01:24:15 - The value in negative findings: ITP studies of green tea extract, methylene blue, curcumin, and more 01:27:00 - 17α-Estradiol: lifespan effects in male mice, and sex-specific effects of different interventions 01:33:15 - Testing ursolic acid and hydrogen sulfide: rationale and preliminary results 01:35:45 - Canagliflozin (an SGLT2 inhibitor): exploring the impressive lifespan results in male mice 01:42:30 - The failure of metformin: reconciling negative results of the ITP with data in human studies 01:48:45 - Nicotinamide riboside: insights from the negative results of the ITP study 01:55:30 - The three most important takeaways from the ITP studies 01:59:30 - Philosophies on studying the aging process: best model organisms, when to start interventions, which questions to ask, and more 02:08:00 - Seven reasons why pigs can't fly Show notes page: https://peterattiamd.com/richardmiller/ About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 30 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://peterattiamd.com/ Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Play: http://bit.ly/TheDriveGooglePlay

🎤 SPEAKERS

• Dr. Richard Miller

  guest

  Physician-scientist at the University of Michigan and a leading figure in the NIA Interventions Testing Program (ITP) for longevity drugs.

🧾 EPISODE SUMMARY

In this episode of Peter Attia MD, featuring Dr. Peter Attia and Dr. Richard Miller, #148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the ITP explores richard Miller on the ITP: Which Drugs Truly Extend Mouse Lifespan Miller explains that the ITP runs in parallel at three sites using large numbers of genetically heterogeneous mice, giving statistically powerful and reproducible tests of whether a drug extends lifespan.

🔗 RELATED EPISODES

409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles

#117 – Stanley Perlman, M.D., Ph.D.: Insights from a coronavirus expert on COVID-19

#150-Senator Bill Frist, MD: A modern Renaissance man's journey through science, politics & business

#130 - Carol Tavris, Ph.D. & Elliot Aronson, Ph.D.: Recognizing and overcoming cognitive dissonance

#96–David Epstein: How range of experience leads to better performance in a highly specialized world

#125 - John Arnold: The most prolific philanthropist you may not have heard of